Physicochemical properties of SARS‐CoV‐2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control

The material properties of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its proteins are discussed. We review the viral structure, size, rigidity, lipophilicity, isoelectric point, buoyant density and centrifugation conditions, stability against pH, temperature, UV light, gamma radiation, and susceptibility to various chemical agents including solvents and detergents. Possible inactivation, downstream, and formulation conditions are given including suitable buffers and some first ideas for quality‐control methods. This information supports vaccine development and discussion with competent authorities during vaccine approval and is certainly related to drug‐targeting strategies and hygienics. Several instructive tables are given, including the pI and grand average of hydropathicity (GRAVY) of SARS‐CoV‐1 and ‐2 proteins in comparison. SARS‐CoV‐1 and SARS‐CoV‐2 are similar in many regards, so information can often be derived. Both are unusually stable, but sensitive at their lipophilic membranes. However, since seemingly small differences can have strong effects, for example, on immunologically relevant epitope settings, unevaluated knowledge transfer from SARS‐CoV‐1 to SARS‐CoV‐2 cannot be advised. Published knowledge regarding downstream processes, formulations and quality assuring methods is, as yet, limited. However, standard approaches employed for other viruses and vaccines seem to be feasible including virus inactivation, centrifugation conditions, and the use of adjuvants.

[1]  K. Subbarao,et al.  Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV , 2004, Journal of Virological Methods.

[2]  Siqi Liu,et al.  Identification of phosphorylation sites in the nucleocapsid protein (N protein) of SARS-coronavirus , 2007, International Journal of Mass Spectrometry.

[3]  Peter Kuhn,et al.  Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy , 2006, Journal of Virology.

[4]  P. Roy,et al.  Efficient assembly and release of SARS coronavirus‐like particles by a heterologous expression system , 2004, FEBS Letters.

[5]  Shengqi Wang,et al.  Subcellular localization and membrane association of SARS-CoV 3a protein , 2005, Virus Research.

[6]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[7]  Gili Kaufman,et al.  Coronaviruses: Propagation, Quantification, Storage, and Construction of Recombinant Mouse Hepatitis Virus , 2011, Current protocols in microbiology.

[8]  Hermann Wätzig,et al.  Precise, fast and flexible determination of protein interactions by affinity capillary electrophoresis. Part 2: Cations , 2013, Electrophoresis.

[9]  Dylan H. Morris,et al.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 , 2020, The New England journal of medicine.

[10]  Samer I. Al-Gharabli,et al.  Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease , 2011, Antiviral Research.

[11]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[12]  H. Doerr,et al.  Stability and inactivation of SARS coronavirus , 2004, Medical Microbiology and Immunology.

[13]  G. Kampf,et al.  Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents , 2020, Journal of Hospital Infection.

[14]  G. Somsen,et al.  One single, fast and robust capillary electrophoresis method for the direct quantification of intact adenovirus particles in upstream and downstream processing samples. , 2017, Talanta.

[15]  I. Wilson,et al.  A structural analysis of M protein in coronavirus assembly and morphology , 2010, Journal of Structural Biology.

[16]  T. Graule,et al.  Isoelectric points of viruses , 2009, Journal of applied microbiology.

[17]  N. Petrovsky,et al.  Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.

[18]  Lukasz P. Kozlowski,et al.  Proteome-pI: proteome isoelectric point database , 2016, Nucleic Acids Res..

[19]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[20]  P. Novák,et al.  Protein Extraction and Precipitation , 2016 .

[21]  H. Wätzig,et al.  The lectin from the mushroom Pleurotus ostreatus: a phosphatase-activating protein that is closely associated with an alpha-galactosidase activity. A part of this paper has been presented as a preliminary report at the 17th Interlec. Meeting 1997 in Würzburg, Germany. , 2001, Plant science : an international journal of experimental plant biology.

[22]  D. Barnard,et al.  Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV , 2011, Vaccine.

[23]  Nobuhiro Fujii,et al.  Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical Reagents , 2006, Dermatology.

[24]  X. Mi,et al.  Virus isoelectric point determination using single-particle chemical force microscopy. , 2019, Langmuir : the ACS journal of surfaces and colloids.

[25]  L. Babiuk,et al.  Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines , 2005, Vaccine.

[26]  G. Whittaker,et al.  Role for Influenza Virus Envelope Cholesterol in Virus Entry and Infection , 2003, Journal of Virology.

[27]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[28]  Lun Song,et al.  Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV , 2020, Cellular & Molecular Immunology.

[29]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[30]  Jiang Gu,et al.  Progress and Prospects on Vaccine Development against SARS-CoV-2 , 2020, Vaccines.

[31]  Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas phase electrophoretic mobility molecular analysis: Part II , 2013, Electrophoresis.

[32]  H. Doerr,et al.  SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation , 2005, Biologicals.

[33]  E. Arriaga,et al.  Recent advances in the analysis of biological particles by capillary electrophoresis , 2008, Electrophoresis.

[34]  Yan Fu,et al.  Low stability of nucleocapsid protein in SARS virus. , 2004, Biochemistry.

[35]  H. Aydin,et al.  Influence of hydrophobic and electrostatic residues on SARS-coronavirus S2 protein stability: Insights into mechanisms of general viral fusion and inhibitor design , 2014, Protein science : a publication of the Protein Society.

[36]  J. Ward,et al.  Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. , 2010, Viral immunology.

[37]  G. Somsen,et al.  Implementation of at‐line capillary zone electrophoresis for fast and reliable determination of adenovirus concentrations in vaccine manufacturing , 2019, Electrophoresis.

[38]  A. D. Russell,et al.  Antiseptics and Disinfectants: Activity, Action, and Resistance , 1999, Clinical Microbiology Reviews.

[39]  G. Allmaier,et al.  Characterization of rhinovirus subviral A particles via capillary electrophoresis, electron microscopy and gas‐phase electrophoretic mobility molecular analysis: Part I , 2012, Electrophoresis.

[40]  Yoshimasa Tanaka,et al.  Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China , 2020, International journal of biological sciences.

[41]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[42]  J. Torres,et al.  Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel , 2009, PLoS pathogens.

[43]  Hermann Wätzig,et al.  A comprehensive platform to investigate protein-metal ion interactions by affinity capillary electrophoresis. , 2015, Journal of pharmaceutical and biomedical analysis.

[44]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[45]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[46]  Deborah R. Taylor,et al.  Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products , 2006, Transfusion.

[47]  H. Nauwynck,et al.  Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges , 2012, Expert review of vaccines.

[48]  Malik Peiris,et al.  Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures , 2020, The Lancet Respiratory Medicine.

[49]  Y. Zhang,et al.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.

[50]  Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, Protein science : a publication of the Protein Society.

[51]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[52]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[53]  S. Morikawa,et al.  Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Krishna Shankara Narayanan,et al.  Severe Acute Respiratory Syndrome Coronavirus 3a Protein Is Released in Membranous Structures from 3a Protein-Expressing Cells and Infected Cells , 2006, Journal of Virology.

[55]  Hyeshik Chang,et al.  The Architecture of SARS-CoV-2 Transcriptome , 2020, Cell.

[56]  B. Fielding,et al.  Coronavirus envelope protein: current knowledge , 2019, Virology Journal.

[57]  S. Lo,et al.  Thermal aggregation of SARS-CoV membrane protein , 2005, Journal of Virological Methods.

[58]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[59]  N. Petrovsky,et al.  Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant , 2015, Methods in molecular biology.

[60]  L. Kremser,et al.  Capillary electrophoresis of viruses, subviral particles and virus complexes. , 2007, Journal of separation science.

[61]  Anton Andonov,et al.  Architecture of the SARS coronavirus prefusion spike , 2006, Nature Structural &Molecular Biology.

[62]  B. Neuman,et al.  Purification of Coronavirus Virions for Cryo-EM and Proteomic Analysis , 2014, Methods in molecular biology.

[63]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[64]  Kaixian Chen,et al.  Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction , 2005, The International Journal of Biochemistry & Cell Biology.

[65]  Shailendra K. Saxena,et al.  Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV) , 2020, VirusDisease.

[66]  P. Hotez,et al.  Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome , 2012, Expert review of vaccines.

[67]  E. Park,et al.  Characterization of human papillomavirus 6b L1 virus-like particles isolated from silkworms using capillary zone electrophoresis. , 2014, Journal of bioscience and bioengineering.

[68]  Mubarak A. Alamri,et al.  Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.

[69]  M. Frieman,et al.  Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.

[70]  Jing Chen,et al.  Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. , 2003, Acta pharmacologica Sinica.

[71]  R. L. Roper,et al.  SARS vaccines: where are we? , 2009, Expert review of vaccines.

[72]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[73]  H. Doerr,et al.  Efficacy of various disinfectants against SARS coronavirus , 2005, Journal of Hospital Infection.